Tundup

Thanks so much ! Did I see the Tilray IPO on Roth’s list of recent deals ? I looked at your post back in June and on the trajectory you provided it appears we will hit 250 events at 3600 patient years @ 7% at mid Dec. ? Amarin formulation of EPA is protected I believe; as is Astra’s Epanova a carboxyl  variation and CaPre which is a phospho version by Acasti . I would think either of these will show better data than Amarin’s Vascepa. Maritech sold out to DKM a while back and these folks among others know how to produce EPA from a sustainable and non contaminated and non marine bioreactor via bacteria I believe. I would point to public literature on nitrated fatty acids and their effects as the next generation of compounds that may leapfrog all of the above for efficacy and which are naturally produced in the human body as well. Many thanks for your insights and sharing .